explore -WSS

explore

author：hotspot 2025-09-27 10:03:43 - browse：72436

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

entertainment

explore

WSS

Medicare wants to send $9 billion to 340B hospitals

Steward Health Care has deal to sell doctor network to UnitedHealth

ACA's risk program benefits Blue Cross Blue Shield insurers

Steward Health Care has deal to sell doctor network to UnitedHealth

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Judge agrees to delay next hearing in Trump classified documents case

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

FDA's naming rule on biosimilars has undermined competition

What does generative AI mean for health care? We asked experts

Biden targets hefty hospital 'facility fees' that often surprise patients

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Merck drug for rare lung condition set for approval in U.S.

How to save PrEP access — and even expand it

Abortion pill case raises question: who can sue the FDA?

Dobbs anniversary: the lost opportunity of abortion as health care

Primary care physicians play key roles in Alzheimer's management

knowledge

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Recent heat wave in the Mediterranean caused by climate change: Study

Parents surprise family after baby discharged from NICU after 170 days

Decaf coffee targeted by food safety group under obscure FDA rule

Covid vaccine financial winners and losers, from Pfizer to Novavax

Readout LOUD podcast: mifepristone case, GLP

entertainment

focus

explore

hotspot